. .
To expand access to a major AIDS drug, ViiV Healthcare and the drug patent pool have reached an agreement that will allow generic drug makers to get Tivicay treatment for four higher-middle-income countries by 50% to 70% versus to offer the existing prices.
The deal will allow lower-cost versions to reach Azerbaijan, Belarus, Kazakhstan and Malaysia after the countries were not excluded from a 2014 licensing agreement that covers dozens of low and middle income countries. Although classified as higher-middle-income countries by the World Bank, all four governments argued that current pricing is preventing treatment for many patients.
STAT is STAT’s premium subscription service for in-depth reporting and analysis in the biotechnology, pharma, politics and life sciences sectors.
Our award-winning team covers the news on Wall Street, Washington policy developments, early scientific breakthroughs and clinical trial results, and health care disruptions in Silicon Valley and beyond.
Dolutegravir, HIV, HIV / AIDS, ViiV Healthcare Limited, GlaxoSmithKline
World News – UK – The Patent Pool for Medicines expands the agreement for access to critical HIV medicines
. . Related title :
– The Medicines Patent Pool extends the agreement on access to essential HIV drugs to several countries with higher middle income
– Malaysia Gets Cheaper Access to Key HIV Drug
– ViiV Healthcare and the Medicines Patent Pool are expanding access to dolutegravir-based therapies for the people they live with . . .
Ref: https://www.statnews.com